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The transcription factor FOXM1 contributes to cell cycle progression and is significantly 
upregulated in basal-like breast cancer (BLBC). Despite its importance in normal and cancer cell 
cycles, we lack a complete understanding of mechanisms that regulate FOXM1. We identified 
USP21 in an RNAi-based screen for deubiquitinases that control FOXM1 abundance. USP21 
increases the stability of FOXM1, and USP21 binds and deubiquitinates FOXM1 in vivo and in 
vitro, indicating a direct enzyme-substrate relationship. Depleting USP21 downregulates the 
FOXM1 transcriptional network and causes a signifi-cant delay in cell cycle progression. 
Significantly, USP21 depletion sensitized BLBC cell lines and mouse xenograft tumors to 
paclitaxel, an anti-mitotic, frontline therapy in BLBC treatment. USP21 is the most frequently 
amplified deubiquitinase in BLBC patient tumors, and its amplification co-occurs with the 
upregulation of FOXM1 protein. Altogether, these data suggest a role for USP21 in the 
proliferation and potentially treatment of FOXM1-high, USP21-high BLBC.
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The cell cycle transcription factor FOXM1 is activated in basal-like breast cancer (BLBC) and 
associated with therapeutic resistance and poor patient outcomes. Arceci et al. show USP21 
antagonizes FOXM1 degradation, thereby promoting proliferation and paclitaxel resistance. 
USP21 is catalytically active and recurrently overexpressed in BLBC, representing a potential 
therapeutic target.
INTRODUCTION
FOXM1 is a member of the forkhead box family of transcription factors, composed of 44 
members in humans, all of which share a conserved forkhead DNA-binding motif (Golson 
and Kaestner, 2016; Hannenhalli and Kaestner, 2009). FOX family transcription factors are 
involved in numerous processes and play particularly important roles in stem cell 
differentiation, proliferation, cell cycle, and metabolism (Myatt and Lam, 2007). FOXM1 is 
best known for its role in regulating the cell cycle, primarily through the transcription of a 
set of targets involved in establishing timely entry into and progression through mitosis 
(Chen et al., 2013; Grant et al., 2013; Laoukili et al., 2005; Sadasivam et al., 2012) and 
ensuring chromosome stability (Laoukili et al., 2005). In addition to its important role in 
normal cell cycles, the periodically expressed cell cycle genes controlled by FOXM1 are 
significantly upregulated in specific cancers and cancer subtypes (Cancer Genome Atlas 
Network, 2012; Cancer Genome Atlas Research Network, 2011; Hoadley et al., 2014).
Breast cancers are stratified into five subtypes, based on molecular features and 
transcriptome-based analysis, that predict outcomes and guide treatment paradigms. The 
molecularly defined basal-like breast cancer (BLBC) subtype largely overlaps with the 
triple-negative classification, named for a lack of overexpression of estrogen receptor (ER), 
progesterone receptor (PR), and HER2 genes (Perou et al., 2000; Sorlie et al., 2003). 
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Outside of mutations to TP53, occurring in 80% of patient tumors, BLBC lacks recurrent 
somatic mutations to known oncogenes and instead exhibits a high degree of chromosome 
instability in the form of copy-number gains and losses, as well as severe aneuploidy 
(Cancer Genome Atlas Network, 2012; Hoadley et al., 2014). Upregulation of the FOXM1 
transcriptional signature represents a defining feature of the BLBC subtype and related 
malignancies, such as high-grade serous ovarian cancer (Cancer Genome Atlas Network, 
2012). Despite the upregulation of FOXM1 in BLBC, it is largely unknown how FOXM1 is 
activated in patient tumors. Because of its roles in the promotion of both cancer and 
chemotherapy resistance (Carr et al., 2010; Zhao et al., 2014), FOXM1 represents an 
attractive anti-cancer treatment target (Halasi and Gartel, 2013a).
FOXM1 is cell cycle regulated, with peak expression and activity occurring during the G2/M 
phase (Korver et al., 1997). FOXM1 is controlled by various post-translational 
modifications, including phosphorylation (Fu et al., 2008; Laoukili et al., 2008b; Major et 
al., 2004) and small ubiquitin-like modifier (SUMO)ylation (Myatt et al., 2014; Schimmel et 
al., 2014); however, it is unclear how these might account for its upregulation in cancer. 
Ubiquitination also plays an important role in FOXM1 regulation. FOXM1 and many of its 
transcriptional targets are ubiquitinated by the anaphase-promoting complex/cyclosome 
(APC/C), thereby triggering their degradation following the onset of mitosis (Laoukili et al., 
2008a; Park et al., 2008). Ubiquitination of FOXM1 by Cul4-VprBP (Wang et al., 2017), 
RNF168 (Kong-sema et al., 2016), SCF-FBXO31 (Jeffery et al., 2017), and FBXW7 (Chen 
et al., 2016) has also been reported. This points to a pivotal role for ubiquitination-dependent 
degradation in regulating FOXM1.
A potential strategy for inactivating FOXM1 may exist by targeting enzymes that prevent 
FOXM1 destruction. To that end, we sought to identify deubiquitinating enzymes (DUBs) 
that regulate FOXM1 stability through the removal of ubiquitin, thus protecting FOXM1 
from degradation. DUBs are catalytic proteases that remove ubiquitin from substrates with 
high in vivo selectivity. The human genome encodes approximately 100 DUBs, which are 
grouped into a growing number of subfamilies (Komander et al., 2009). Several selective 
small-molecule DUB inhibitors have been developed, pointing to their potential drugg-
ability (Kategaya et al., 2017; Turnbull et al., 2017).
By deploying an RNAi-based screen against nucleus-localized DUBs, ubiquitin-specific 
protease 21 (USP21) was identified as a potential regulator of FOXM1 stability. USP21 is a 
member of the ubiquitin-specific protease (USP) family of DUBs, which contains 56 
members unified by a highly conserved USP domain, featuring a catalytic triad essential for 
activity (Komander et al., 2009). USP21 has been linked to transcriptional regulation 
through interaction with the transcription factors NANOG (Jin et al., 2016), GATA3 (Zhang 
et al., 2013), and GLI1 (Heride et al., 2016) as well as histone H2A (Nakagawa et al., 2008).
Here, we demonstrate a substrate-enzyme relationship between FOXM1 and USP21. USP21 
regulates FOXM1 abundance and USP21 binds and removes polyubiquitin chains from 
FOXM1, thus protecting it from proteasomal degradation. We also show that USP21 
expression can alter the FOXM1 transcriptional network, which has consequences in 
regulating mitotic timing and proliferation. Furthermore, we show that FOXM1 and USP21 
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are specifically upregulated in BLBC and that depletion of USP21 can improve sensitivity to 
paclitaxel, primarily through its relationship with FOXM1. These findings demonstrate that 
USP21, through the maintenance of FOXM1 stability, regulates cell cycle progression and 
that inhibiting USP21 has therapeutic potential in treating BLBC with a FOXM1-high, 
USP21-high expression signature.
RESULTS
USP21 Binds and Alters FOXM1 Abundance
To determine whether FOXM1 abundance is regulated by DUB activity, HeLa cells were 
treated with PR-619, a small-molecule, non-specific pan-DUB inhibitor for 8 h. Immunoblot 
(IB) analysis revealed that FOXM1 abundance significantly decreased with increasing 
concentrations of PR-619 (Figure 1A). This suggested that the degradation of FOXM1 could 
be actively prevented by DUBs.
To discover specific USP-family DUBs that directly affect FOXM1 abundance, HeLa cells 
were transfected with pooled small interfering RNAs (siRNAs) against a subset of USP-
family DUBs that show nuclear localization. IB analysis of cell lysates 48 h after 
transfection revealed that USP21 knockdown reproducibly reduced the level of endogenous 
FOXM1 (Figure 1B). Deconvolution of the siRNA pool revealed that multiple, independent 
siRNAs reagents targeting USP21 reduced the protein levels of FOXM1 (Figure S1A). 
Furthermore, FOXM1 abundance was not significantly reduced in cells stably expressing a 
FLAG- and hemagglutinin (HA)-tagged USP21 variant made resistant to USP21 siRNA 
(Figure S1B), demonstrating that the reduction in FOXM1 abundance is specifically linked 
to an on-target effect of USP21 knockdown. Correspondingly, ectopic expression of USP21 
significantly increased FOXM1 abundance in 293T cells (Figure 1C). These results 
demonstrate that FOXM1 abundance is regulated by USP21.
To determine whether the effects on FOXM1 stability resulting from changes of USP21 
expression were due to an interaction between the two proteins, FLAG- or HA-tagged 
FOXM1b and Myc-USP21 plasmids were ectopically expressed in 293T cells. An 
interaction between FOXM1 and USP21 was detected by coimmunoprecipitation (co-IP), 
regardless of whether the immuno-precipitation (IP) was directed against Myc-USP21 
(Figure 1D) or HA-FOXM1b (Figure 1E). In addition, an interaction between endogenous 
FOXM1 and USP21 was detected using antibodies directed against USP21 (Figure 1F). To 
determine the domain on FOXM1 recognized by USP21, a series of Myc-FOXM1b 
fragments (Figure S1C) was co-transfected with FLAG-HA-USP21 into 293T cells and 
interactions were assessed by co-IP. Results from IP directed against both Myc-FOXM1b 
(Figure S1D) and FLAG-HA-USP21 (Figure S1E) demonstrate that USP21 binds to a region 
encompassing FOXM1 amino acids 321–400.
Because exogenous and endogenous FOXM1 and USP21 can interact in vivo, we assessed 
their binding in vitro by incubating recombinant, bacterially produced hexa-histidine 
(6xHIS)-tagged FOXM1b with recombinant, bacterially produced, glutathione S-transferase 
(GST)-tagged USP21. 6xHIS-FOXM1b was detected in complex with GST-USP21 
following pull-down on glutathione resin (Figure 1G). Altogether, these data demonstrate 
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that USP21 and FOXM1 directly interact, strongly suggesting an enzyme-substrate 
relationship between the two proteins.
FOXM1 Is a USP21 Substrate
FOXM1 is a known substrate of several E3-ubiquitin ligases, including APC/C (Laoukili et 
al., 2008a; Park et al., 2008) and Cul4-VprBP (Wang et al., 2017), which can conjugate 
polyubiquitin chains onto FOXM1, triggering its subsequent proteasomal degradation. To 
determine whether the effects that USP21 knockdown or overexpression has on FOXM1 are 
mediated through proteasomal degradation, HeLa cells transfected with siRNA targeting 
firefly luciferase (siFF; control) or siRNA targeting USP21 (siUSP21) were treated with the 
proteasome inhibitor MG132. IB analysis confirms that FOXM1 destabilization resulting 
from USP21 knockdown is partially rescued through protea-some inhibition (Figure 2A).
DUBs oppose proteasomal degradation through removal of polyubiquitin chains, particularly 
K48 and K11 topologies, and USP21 has been shown to cleave both of these polyubiquitin 
linkages in vitro (Ye et al., 2011). To determine whether USP21 influences polyubiquitin 
chain conjugation on FOXM1, we analyzed FOXM1 ubiquitination in vivo. 293T cells were 
transfected with HA-FOXM1b and 6xHIS-FLAG-Ubiquitin in combination with either wild-
type USP21 (USP21WT) or a catalytically dead variant of USP21 (cystine at amino acid 
position 221 changed to alanine; USP21C221A). 24 h post-transfection, cells were harvested 
and lysed under denaturing conditions, subjected to pull-down on nickel-charged 
nitrilotriacetic acid (Ni-NTA) resin to enrich for ubiquitinated proteins, and analyzed by IB. 
Polyubiquitinated FOXM1 (FOXM1 ≥ 100 kDa at the top of Figure 2B) was readily 
detectable under conditions with endogenous levels of USP21 expression (Figure 2B, lane 
2), but it was greatly diminished by overexpression of USP21WT (Figure 2B, lane 3). 
However, levels of polyubiquitinated FOXM1 were restored close to levels observed in 
control conditions when USP21C221A was overexpressed (Figure 2B, lane 4). Similarly, 
USP21WT, but not USP21C221A, immunopurified from 293T cells reduced 
polyubiquitination of FOXM1 isolated from proteasome inhibitor-treated 293T cells in an in 
vitro deubiquitination assay (Figure S2A).
Because USP21 can directly bind and deubiquitinate FOXM1, we next evaluated the impact 
of USP21 on FOXM1 stability. To assess the effect of USP21 on FOXM1 half-life, FOXM1 
levels were assessed by IB following overexpression of either USP21WT or USP21C221A in 
293T cells (Figure 2C) and depletion of USP21 in BLBC MDA-MB-231 cells (Figure S2B) 
treated with cycloheximide to block protein translation. FOXM1 abundance decreases with 
similar kinetics over the first 4 h following cycloheximide treatment in all conditions, but 
USP21WT overexpression can protect the remaining population from degradation for at least 
another 12 h, whereas FOXM1 abundance falls even more rapidly in USP21C221A cells than 
in control cells after this point (Figure 2C). Half-life quantified from the best-fit curve for 
FOXM1 in control cells is approximately 7.6 h. The expression of USP21WT increased 
FOXM1 stability, and its half-life was approximately 12.4 h. In contrast, ectopic expression 
of USP21C221A shortened FOXM1 half-life to approximately 3.7 h, consistent with it having 
a dominant-negative effect on FOXM1 stability, as well as controlling its own ubiquitination 
(Figure S2B). Similarly, depletion of USP21 in MDA-MB-231 reduced FOXM1 half-life 
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from 11.5 to 4.2 h (Figure S2C). Altogether, these results indicate that USP21 controls 
FOXM1 ubiquitination and proteasomal-mediated degradation.
USP21 Affects the FOXM1 Transcriptional Network and Proliferation
FOXM1 is the master transcriptional regulator of a set of genes involved in establishing and 
ensuring a successful G2/M transition and progression through mitosis. Dysregulation of 
this transcriptional network has been shown to induce cell cycle delays, mitotic defects, and 
mis-segregation of chromosomes (Laoukili et al., 2005). We hypothesized that modulating 
USP21 levels would have corresponding effects on FOXM1 transcriptional output because 
of its effects on stabilizing FOXM1. To determine the effect that USP21 overexpression has 
on FOXM1 activity, 293T cells were co-transfected with USP21 and a FOXM1 luciferase-
based transcriptional activity reporter (6x-DBE) (Furuyama et al., 2000). USP21 
overexpression significantly enhanced FOXM1-dependent transcriptional activity compared 
with control (Figure 3A). This is consistent with our previous data demonstrating that 
FOXM1 abundance is positively enhanced by USP21 overexpression. Correspondingly, a 
panel of FOXM1 transcriptional targets was assessed by RT-qPCR following siRNA 
transfection to knockdown either FOXM1 or USP21 in MDA-MB-231 cells. Knockdown of 
USP21 leads to a reduction in all FOXM1 transcriptional targets assessed compared with 
controls (Figure 3B, compare red bars to black bars). USP21 knockdown did not lead to the 
same decrease in FOXM1 transcriptional target abundance as FOXM1 knockdown (Figure 
3B, compare red bars to orange bars); however, this is consistent with biochemical data 
demonstrating that USP21 knockdown reduces FOXM1 levels to an amount between what is 
observed in control conditions and what is observed in FOXM1 knockdown conditions 
(Figure 3C). In addition, USP21 over-expression did not significantly alter FOXM1 mRNA 
levels in MDA-MB-231 cells transduced with a pINDUCER20 lentivirus to introduce a 
doxycycline-inducible USP21 transgene (Meerbrey et al., 2011) (Figure S3A). Altogether, 
these data demonstrate that changes in FOXM1 levels because of USP21 have downstream 
effects on the FOXM1 transcriptional network.
Tight regulation of the FOXM1 transcriptional network is required for a timely and high-
fidelity transition from G2 to mitosis. Having demonstrated that USP21 levels can affect the 
FOXM1 transcriptional network, we next sought to determine whether the kinetics of mitotic 
entry are disrupted by USP21 loss. To observe effects on mitotic timing, the accumulation of 
phospho-histone H3 S10 (P-H3) following release of cells from synchronization at the G1/S 
boundary with aphidicolin was monitored in MDA-MB-231 cells depleted of FOXM1 or 
USP21. In parallel, we analyzed cells in which FOXM1 was ectopically expressed in 
USP21-depleted cells (Figure S3B). Following release from synchronization, cells were 
treated with the microtubule poison nocodazole so that they would get trapped in mitosis, 
allowing us to determine the percentage of cells that had entered mitosis throughout the 
duration of the experiment. Depletion of either FOXM1 or USP21 significantly impaired cell 
cycle progression into mitosis. 22 h after release, only 1.6% and 10.9% of cells were P-H3 
positive in FOXM1- and USP21-depleted populations, respectively (Figure 3D; Figure S4). 
In contrast, 40.7% of control cells had entered mitosis by that time. Mitotic entry was 
significantly rescued (27.4% of cells were P-H3 positive) in the USP21-depleted-FOXM1 
overexpression populations. These results confirm prior reports that FOXM1 knockdown 
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impairs mitotic entry (Laoukili et al., 2005). Furthermore, they demonstrate that USP21 
promotes progression through mitosis, because its depletion severely impairs the 
accumulation of mitotic cells. Because this defect is largely rescued by forced FOXM1 
expression, the cell cycle phenotype in USP21-depleted cells occurs largely because of the 
reduction of FOXM1 abundance.
Finally, we hypothesized that slowed mitotic entry resulting from FOXM1 and USP21 
knockdown would cause a corresponding reduction in proliferation. Proliferation was 
significantly impaired in the BLBC cell lines MDA-MB-468 and MDA-MB-231 (Figure 
3E). In addition, ectopic, doxycyclineinducible expression of FOXM1b in MDA-MB-231 
cells partially rescued the impaired proliferation caused by USP21 depletion. Similar results 
were observed in HeLa cells over a four-day period (Figure S3C). Thus, downregulation of 
USP21 can affect overall proliferation by downregulating both FOXM1 stability and 
downstream effects of the FOXM1 transcriptional network.
USP21 Amplification Correlates with FOXM1 Protein Levels and Tumor Proliferation in 
BLBC
FOXM1 upregulation has been reported in various cancers (Cancer Genome Atlas Network, 
2012; Cancer Genome Atlas Research Network, 2011; Kalin et al., 2006; Kim et al., 2006; 
Liu et al., 2006). In breast cancer, we found that FOXM1 mRNA expression is significantly 
correlated with breast cancer sub-types, showing the highest expression in the BLBC 
subtype (t test basal versus non-basal, p ≤ 2.2 × 10−16) (Figure 4A, top). This is consistent 
with prior genomic studies that found the FOXM1 transcriptional signature upregulated in 
BLBC (Cancer Genome Atlas Network, 2012). We next analyzed the proliferative capacity 
of tumors in which FOXM1 is activated. The proliferation score of individual tumors was 
highly and significantly correlated with FOXM1 expression, both across all breast cancer 
subtypes and within individual subtypes. That is, a tumor proliferation score increases as a 
function of FOXM1 mRNA expression among all patient breast tumors even within only the 
luminal A breast cancers (Figure 4A, top, blue dots), which generally proliferate more 
slowly than more aggressive HER2-enriched and BLBC subtypes. As expected, expression 
analysis of well-established FOXM1 transcriptional targets revealed a corresponding 
upregulation in FOXM1-high, BLBC patient samples (Figure 4A, bottom). We conclude that 
FOXM1 expression and activity exist on a sliding scale, with increasing FOXM1 levels 
alone being a strong indicator of tumor proliferation.
Next, we analyzed copy number changes and mRNA expression for all human DUBs among 
breast tumors in the The Cancer Genome Atlas (TCGA) dataset. USP21 is the fourth-most 
frequently copy number alteration (CNA)-amplified and the most frequently mRNA-
overexpressed DUB across all patient samples (Figure 4B), with USP21 amplification 
significantly correlated with both proliferation score and BLBC subtype (Figure S5A). The 
genomic location of USP21 is 1q23. This region is the most frequently amplified region in 
BLBC patient tumors (Silva et al., 2015; Weigman et al., 2012). However, this amplicon 
lacks a well-described oncogene that contributes to disease. Correspondingly, IB analysis of 
FOXM1 and USP21 protein expression in cell lines representing the normal-like, luminal, 
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and BLBC subtypes of breast cancer revealed that expression of FOXM1 and USP21 is 
uniquely high in the BLBC subtypes (Figure 4C; Figure S5B).
FOXM1 is among the 227 proteins and/or antigens profiled by reverse-phase protein array 
(RPPA) in TCGA. This provided us the opportunity to examine the abundance of FOXM1 
protein levels in breast cancer and its relationship to USP21 mRNA expression in tumors. 
Because our results demonstrate that the FOXM1 protein is post-translationally stabilized by 
USP21, we examined FOXM1 protein levels as a function of USP21 expression. FOXM1 
protein is the most significantly upregulated protein and/or antigen in USP21-amplified 
tumors (Figure 4D). Among the other most statistically significant increasing proteins were 
the FOXM1 targets cyclin B1, the cell cycle-regulated gene MSH6 (Fischer et al., 2016), 
adenosine deaminase ADAR1 (which is proximal to the genetic location of USP21), and the 
asparagine deaminase ASNS, which has been previously implicated in breast cancer 
proliferation and cell cycle progression (Yang et al., 2014). Because FOXM1 is upregulated 
by USP21, we asked whether a curated list of 114 FOXM1 target genes is correlated with 
USP21 amplification using gene set enrichment analysis (GSEA). This analysis revealed 
strong enrichment for the FOXM1 transcriptional network in USP21-amplified breast 
cancers (Table S1).
USP21 Affects Paclitaxel Response in BLBC
In addition to its role in cancer proliferation, high FOXM1 expression has been attributed to 
resistance to platinum-based drugs (Zhou et al., 2014) and taxanes (Carr et al., 2010; Zhao et 
al., 2014) in breast cancer and correlated with metastasis and poor patient outcomes. Having 
identified FOXM1 as a USP21 substrate, we examined whether USP21 knockdown could 
increase sensitivity to paclitaxel in a FOXM1-dependent manner. The BLBC cell lines 
MDA-MB-231 and MDA-MB-468 and SUM149 cells were used to assess viability 
following 72 h of exposure to DMSO or paclitaxel in control (siFF), FOXM1-depleted 
(siRNA targeting FOXM1 [siFOXM1]), and USP21-depleted (siUSP21) cells. In addition, in 
MDA-MB-231 cells, we used a cell line containing a stably integrated, doxycyclineinducible 
version of FOXM1, allowing us to examine viability in USP21-depleted-FOXM1-induced 
(siUSP21 + FOXM1b) conditions. Across all cell lines assessed, there is a significant 
reduction in viability between FOXM1- and USP21-depleted conditions treated with 
paclitaxel compared with the same depletion condition in which cells were not treated with 
paclitaxel (DMSO control) (Figure 5A). Therefore, while depletion of USP21 (and FOXM1) 
impairs proliferation in each of these cell lines under control conditions, there is a 
statistically significant decrease in viability when USP21 depletion is combined with 
paclitaxel treatment. Specifically, in MDA-MB-231 cells exposed to paclitaxel, cell viability 
was reduced by 40.9% and 38.3% compared with control in FOXM1- and USP21-depleted 
conditions, respectively (Figure 5A, top). However, cell viability is only reduced by 16.7% 
in cells in which USP21 was depleted but FOXM1 levels are restored with doxycycline 
induction. In MDA-MB-468 cells treated with paclitaxel, viability was more strongly 
reduced, by 81.3% and 41.5% compared with control in FOXM1- and USP21-depleted 
conditions, respectively (Figure 5A, middle). Finally, in SUM149 cells treated with 
paclitaxel, viability was significantly reduced, by 43.6% and 20.2% in FOXM1- and USP21-
depleted conditions, respectively (Figure 5A, bottom). This is particularly striking 
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considering that SUM149 cells do not show a significant reduction in viability when treated 
with paclitaxel alone. The significant difference in cell viability resulting from FOXM1 
depletion and USP21 depletion combined with a significant rescue of viability when 
FOXM1 is overexpressed in the USP21-depleted conditions suggests that FOXM1 
significantly contributes to paclitaxel sensitivity and is a critical USP21 substrate, although 
perhaps not the only one, contributing to the differences in paclitaxel sensitivity observed in 
USP21-depleted cells.
Based on the realization that USP21 depletion sensitizes cells to paclitaxel, we next 
determined how BLBC cells would respond to paclitaxel following USP21 depletion in a 
mouse xenograft model. SUM149 is a BLBC cell line that is paclitaxel insensitive in mouse 
xenografts (Figure 5B, red line). SUM149 cells were transduced with lentivirus expressing 
scrambled short hairpin RNA (shRNA) (shControl) or shRNA targeting USP21 (shUSP21) 
and implanted in the mammary fat pads of non-obese diabetic (NOD)-severe combined 
immunodeficiency (SCID) gamma mice following selection for infected cells (Figure S5C). 
Mice were then administered either paclitaxel (10 mg/kg of body weight) or vehicle twice 
weekly, and tumor volume was monitored twice weekly for six weeks. The results revealed 
that average tumor volume was reduced from 1,101.75 mm3 in the control condition to 414 
mm3 (a 62.4% reduction) over six weeks because of depletion of USP21 and exposure to 
paclitaxel (Figure 5B, blue line). These results suggest that inhibition of USP21 may provide 
a therapeutic benefit in BLBC by antagonizing proliferation and enhancing chemotherapy 
resistance effects driven by FOXM1 activation.
DISCUSSION
Here, we identify the transcription factor FOXM1 as a substrate of the DUB USP21. USP21 
stabilizes FOXM1, and suppressing USP21 reduces FOXM1 abundance, which subsequently 
downregulates the FOXM1 transcriptional network. This leads to a mitotic entry delay, 
slowed proliferation, and sensitivity to paclitaxel, both in culture and in animal xenografts. 
Phenotypes linked to USP21 depletion were partially mitigated by forced expression of 
FOXM1. This suggests that FOXM1 is a key USP21 substrate with respect to these 
phenotypes but likely is not the only target determining the role of USP21 in the cell cycle, 
cancer proliferation, and paclitaxel sensitivity. Nevertheless, we predict that targeting USP21 
could have therapeutic potential in aggressive cancers marked by high FOXM1 expression 
and with concordant genome instability.
To date, few USP21 substrates have been identified. Many validated substrates, including 
GATA3 (Zhang et al., 2013), GLI1 (Heride et al., 2016), NANOG (Jin et al., 2016), and 
ubiquitinated histone H2A K119 (Nakagawa et al., 2008), are either transcription factors or 
involved in the regulation of transcription. Our identification of FOXM1, a transcription 
factor that regulates cell cycle progression, as a USP21 substrate supports this theme. Given 
these roles, it is interesting to consider USP21 as a general transcriptional regulator through 
its dual function in stabilizing transcription factors and creating a permissive landscape for 
transcription to occur through the removal of ubiquitin at H2A K119, a post-translational 
modification associated with transcriptional repression. Future work integrating these 
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aspects of transcription under the control of USP21 may underscore its importance in the 
promotion of transcriptional activity.
BLBC is characterized by high genomic instability, which contributes to a distinctive pattern 
of CNA gains at 1q, 6p, 8q, and 10p, along with frequent losses at 4p, 5q, 14q, and 15q 
(Adélaïde et al., 2007). Outside of TP53 loss, which occurs in more than 80% of cases, there 
are few mutations in well-characterized oncogenes or additional tumor suppressors linked to 
BLBC. The USP21 genomic location is 1q23, an amplified region suggested to contain 
putative driver genes for the BLBC subtype (Silva et al., 2015). The FOXM1 genomic 
location is 12p13, another amplified region associated with the BLBC subtype. Our analysis 
supports links of FOXM1 expression, the BLBC subtype, and proliferation, as well as a 
correlation between USP21 expression at the genomic and transcriptional levels (Figure 4B) 
and a correlation between USP21 and FOXM1 levels in BLBC. We show that USP21 
amplification correlates with proliferation score of the tumor. While this result is partially 
complicated by amplification of 1q and particularly the USP21 genomic locus, being 
enriched in aggressive BLBC-subtyped tumors (Silva et al., 2015), this points to its potential 
role in disease. The evidence presented here suggests that USP21 could act as a proliferative 
driver by promoting FOXM1 stability and transcriptional function, which promotes 
proliferation in BLBC with amplified USP21 and FOXM1 expression. We speculate that 
increased gene dosage of USP21 contributes to the proliferative features of BLBC and that it 
likely acts coordinately with additional proliferative drivers on 1q, as well as with other 
genes located within recurrently altered genomic regions.
Because of its myriad roles in the promotion and maintenance of cancer, FOXM1 has 
garnered significant attention as a target for therapeutic intervention (Halasi and Gartel, 
2013b). Because FOXM1 is recurrently activated in specific disease subtypes, including 
most BLBC and high-grade serous ovarian cancers, the rationale, therapeutic window, and 
patient numbers exist to support its therapeutic candidacy. Moreover, while therapies that 
target specific transcription factors are clinically effective, including hormone therapy in 
breast cancer and all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (Bradner 
et al., 2017), in most cases, transcription factors have defied efforts aimed at chemical 
inhibition (e.g., c-Myc).
Here, we provide the rationale for an indirect method of down-regulating FOXM1 activity 
through the inhibition of USP21. In contrast with transcription factors, DUBs have favorable 
properties that make them attractive therapeutic targets. More specifically, USP-family 
DUBs have deep, active pockets relying on a catalytic triad (Komander et al., 2009) that is 
generally tractable with small-molecule inhibitors (Shi and Grossman, 2010). The 
identification of potent and highly selective USP7 inhibitors has brought to the forefront the 
chemical tractability of DUBs as a therapeutic class (Kategaya et al., 2017; Turnbull et al., 
2017). The crystal structure of the USP21 catalytic core has been solved (Ye et al., 2011), 
which facilitates the identification and development of potent and highly selective small-
molecule inhibitors through structure-activity relationship studies. Future work describing 
additional substrates and processes influenced by USP21 may uncover additional examples 
in which USP21 inhibition may demonstrate therapeutic benefit.
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Detailed methods are provided in the online version of this paper and include the following:
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Michael J. Emanuele (emanuele@email.unc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines—293T, HeLa, MDA-MB-231, MDA-MB-468, HMEC, MCF7, MCF10A and 
BT474 cells were all obtained from the American Type Culture Collection (ATCC). 
SUM149 and SUM159 cells were obtained from BioIVT (formerly Astrand). All cell lines 
are female.
Mouse Model—All mouse studies were conducted following an Institute of Animal Care 
and Use Committee (IACUC)-approved protocol. BALB/c female nude mice (nu/nu) bread 
by the UNC-Chapel Hill Mouse Phase 1 Unit (MP1U) were used at 8 weeks of age, housed 
four per cage and provided sterilized pellet chow and given tap water ad libitum. Animal 
rooms are maintained at 22°C and lighted 16 hours per day.
METHOD DETAILS
Cell Culture—Cell lines were all obtained from the American Type Culture Collection, or 
BioIVT. 293T, HeLa, MDA-MB-231, MDA-MB-468, HMEC, MCF7, MCF10A, SUM159, 
and BT474 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) 
supplemented with 10% FBS (Atlanta Biologicals) and 1% Pen/Strep (GIBCO). SUM149 
cells were obtained from BioIVT and cultured in either F-12 medium (GIBCO) 
supplemented with 5% FBS (Atlanta Biologicals), 10mM HEPES pH7.5, 1μg/mL 
hydrocortisone, 5μg/mL insulin (GIBCO) and 1% Pen/Strep (GIBCO) or in HuMEC Ready 
Medium (GIBCO). All cells were incubated at 37°C and 5% CO2.
Transfections and Treatments—All siRNA transfections were performed using 
Lipofectamine RNAiMAX (ThermoFisher) following instructions in the manufacturer’s 
instructions. Sequence of siRNAs used in this study are described in Table S2. All plasmid 
transfections into 293T cells were performed using Mirus TransIT-293 reagent (Mirus Bio) 
following instructions in the manufacturer’s protocol. Plasmid transfections into other cell 
lines were performed using Lipofectamine 2000 (ThermoFisher) according to 
manufacturer’s instructions. PR-619 and MG132 (Selleck Chemicals) were used at a 
concentration of 10μM for 8 hours and 6 hours, respectively. Cycloheximide 
(MilliporeSigma) was used at a concentration of 100ng/mL for the indicated time.
Molecular Cloning—pDEST-HA-FOXM1b, pDEST-Myc-USP21, pDEST-FLAG-
FOXM1b, pINDUCER20-FOXM1b and pINDUCER20 USP21 were all generated using 
Gateway Cloning Technology (ThermoFisher) from pDONR223-FOXM1b and pDONR223-
USP21 plasmids. All FOXM1 fragments described in Figure S1 were ordered as synthetic 
gene fragments (IDT) and subsequently cloned into pDONR223 and pDEST-Myc plasmids 
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for expression using Gateway Cloning Technology. The FOXM1 6x-DBE luciferase reporter 
plasmid was a gift from Michael Whitfield (Dartmouth Univsersity). FLAG-HA-USP21 
plasmid was a gift from Wade Harper (Addgene plasmid # 22574) (Sowa et al., 2009). 
pINDUCER20 was a gift from Stephen Elledge (Addgene plasmid # 44012) (Meerbrey et 
al., 2011). 6-HIS-FLAG Ubiquitin plasmid was a gift from Philippe Soubeyran. Site-directed 
mutagenesis with QuickChange Lightning Kit (Agilent) was used to generate C221A 
MSCV-FLAG-HA-USP21 following manufacturer’s instructions. Primers used are described 
in Table S2.
Lentivirus Production—293T cells were transfected with pINDUCER20 plasmids mixed 
with VSV-G, Gag-Pol, Tat and Rev lentivirus packaging helper plasmids in a 1:4 ratio. 
Media containing viral particles was harvested 24 and 48 hours later, passed through a 
0.45μM filter and stored frozen at −80°C. MDA-MB-231 cells were transduced with 
lentiviral particles and selected with G418 to isolate successfully transduced cells.
Immunoblotting—Samples were lysed in RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 
5mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 
1μg/mL aprotinin and leupeptin, 10μg/mL leupeptin, 1mM sodium orthovanadate, 1mM 
NaF, and 1mM AEBSF. Protein concentration was quantified by Pierce BCA assay 
(ThermoFisher) and samples were prepared by boiling in Laemmli buffer for 5 minutes. 
Samples were separated by gel electrophoresis using homemade or TGX (Bio-Rad) SDS-
PAGE gels and transferred to nitrocellulose membrane. All blocking and antibody washing 
steps were performed in 5% nonfat dried milk (Bio-Rad) diluted in TBS-T (137mM NaCl, 
2.7mM KCl, 25mM Tris pH 7.4, 1% Tween-20). All primary antibody incubations were 
performed shaking at 4°C for 16 hours. All secondary antibody incubations were performed 
shaking at room temperature for 1 hour. All washing steps were performed using TBS-T. 
Protein abundance was visualized by chemiluminescence using Pierce ECL (ThermoFisher), 
or Clarity ECL (Bio-Rad). A list of all antibodies used in this study are described is Table 
S2.
Immunoprecipitations—293T cells were transfected with the indicated plasmids and 
lysed in NETN buffer (100mM NaCl, 20mM Tris pH 8, 0.5mM EDTA, 0.5% NP-40 
supplemented with 1μg/mL aprotinin and leupeptin, 10μg/mL leupeptin, 1mM sodium 
orthovanadate, 1mM NaF, and 1mM AEBSF) 48 hours after transfection. 1μg of the 
indicated antibody was conjugated to a 50μl mix of magnetic Protein A and Protein G beads 
(Bio-Rad) at room temperature for 1 hour. 1mg of lysate from each sample was pre-cleared 
to remove non-specific interactions with a similar volume of Protein A/G beads rotating at 
4°C for 1 hour. Following antibody conjugation and pre-clearing, lysate and beads were 
combined rotating at 4°C for 4 hours. Beads were subjected to multiple rounds of washing 
with NETN. Proteins were eluted by boiling beads in Laemmli buffer for 10 minutes and 
visualized by IB.
FOXM1 and USP21 In Vitro Binding Assay—FOXM1b was subcloned into a pET-28b 
backbone to create a C-terminal 6X-Histidine tagged clone, transformed into Escherichia 
coli BL21(DE3) cells, grown to an OD600 of 0.5, and induced to express with 250μM of 
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IPTG shaking at 18°C for 16 hours. USP21 was cloned into a pDEST15 backbone using 
Invitrogen Gateway cloning technology (ThermoFisher) to create a N-terminal GST-tagged 
clone, transformed into Escherichia coli BL21(DE3) cells, grown to an OD600 of 0.5, and 
induced to express with 100μM of IPTG shaking at 25°C for 5 hours. Bacterial pellets were 
resuspended in 40mL lysis buffer (20mM KH2PO4 pH 7.5, 500mM NaCl, 10% glycerol, 
2μg/mL aprotinin, 10μg/mL leupeptin, 2μg/mL pepstatin, 1mM sodium orthovanadate, 1mM 
NaF 1mM AEBSF, 10mg/mL lysozyme, 40U DNase I; leupeptin and AEBSF not included 
in GST-USP21 lysis). 6HIS-FOXM1b and GST-USP21 were batch purified from crude 
lysate on His-Pur Ni-NTA resin (ThermoFisher) and glutathione agarose resin (GoldBio) 
following manufacturer’s protocols, respectively. Following elution, proteins were buffer 
exchanged (25mM Tris pH 7.4, 200mM NaCl, 2mM DTT) using Zeba desalting columns 
(ThermoFisher) following manufacturer’s protocols. For interaction studies, 1mg of GST or 
GST-USP21 was conjugated to GSH agarose resin rotating at room temperature for 1 hour. 
Then, 1μg 6HIS-FOXM1b was added and incubation continued with rotation at room 
temperature for 1 hour. Following three rounds of washing with PBS, protein complexes 
were eluted (50mM Tris pH 8.0, 10mM glutathione), resuspended in Laemmli buffer and 
assessed by IB.
FOXM1 Transcriptional Reporter Assay—293T cells were transfected with FOXM1 
6x-DBE luciferase reporter and FLAG-HA-USP21 plasmids as indicated and collected 24 
hours after transfection. Lysates were prepared according to the protocol described in the 
Luciferase Assay System (Promega). Measurements were made in a 96-well plate and 
results represent the average of triplicates for each experiment condition described.
Cell Cycle Progression into Mitosis—MDA-MB-231 cells were transfected with the 
indicated siRNA using RNAiMAX. 48 hours following transfection, media on cells was 
refreshed with media containing 2μg/mL aphidicolin. 24 hours later, media on cells was 
refreshed with media containing 200ng/mL nocodazole. Cells were harvested at the 
indicated time points and samples were prepared for IB or for flow cytometry by fixation in 
70% ethanol. For flow cytometry, cells were blocked for 30 minutes, incubated with rabbit 
anti-phospho-Histone H3 (S10) antibody for 1 hour, then incubated with goat anti-rabbit 
Alexa Fluor 488 for 1 hour, and finally stained with 25μg/mL propidium iodide, 100μg/mL 
RNase A for 1 hour. All blocking, washing, and staining steps were done with 1% BSA in 
PBS. All samples were run on a CyAn ADP analyzer (Beckman Coulter) and data was 
analyzed using FlowJo X software.
In Vitro Paclitaxel Sensitivity Assays—MDA-MB-231 pINDUCER20-FOXM1b, 
MDA-MB-468 and SUM149 cells were transfected with the indicated siRNAs. 24 hours 
following transfection, cells were seeded in triplicates at a density of 7,500 cells / well in a 
96-well plate. 12 hours after seeding, media supplemented with paclitaxel, and in one set of 
siUSP21 triplicates (MDA-MB-231 pINDUCER20 FOXM1b only), paclitaxel with 
10ng/mL doxycycline was added to cells. After a 72-hour incubation, cell viability was 
assessed using PrestoBlue reagent according to manufacturer’s instructions.
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Tumor Xenograft—SUM149 cells were transduced with lentivirus expressing shRNA 
against USP21 or a non-targeting control and selected of positive expression with 
puromycin. Immediately following selection, orthotopic xenografts were established for all 
conditions by injecting subcutaneously 5 × 106 cells mixed 50:50 in serum-free 
media:matrigel into the right mammary fat pad of athymic, female nude mice. Tumor 
volume was measured with calipers and calculated using the equation Volume = Length × 
Width2 × 0.563. Upon tumors reaching a volume 100mm3, mice were administered a bi-
weekly intraperitoneal injection of 10mg/kg (body weight) paclitaxel or equivalent volume 
of vehicle. Tumor volume measurements were recorded twice weekly for 6 weeks.
Proliferation Assays—MDA-MB-231 pINDUCER20 FOXM1b and MDA-MB-468 cells 
were transfected with the indicated siRNA, then 12 hours later, 30,000 cells/well were 
seeded into 24-well plates in triplicates for each condition. Growth was monitored through 
phase-contrast imaging using the IncuCYTE Zoom (Essen Bioscience) live-cell imaging 
device. Images were taken every 6 hours for 120 total hours and growth was calculated for 
each time point as the average percent confluence of 4 images taken per well. Values were 
normalized for each respective condition so initial confluence starts at 0%.
HeLa cells were transfected with the indicated siRNA, then 24 hours later, transfected with 
the indicated plasmids. Growth was monitored using PrestoBlue cell viability reagent 
(ThermoFisher) following the manufacturers protocol. Measurements were taken in 
triplicate for each time point with each point described as a percentage of the first 
measurement taken following seeding.
In Vivo Deubiquitination Assay—The in vivo ubiquitination assay was performed as 
described previously (Bonacci et al., 2014). Briefly, 293T cells were transfected with the 
indicated plasmids and harvested in PBS 24 hours following transfection. 80% of the cell 
suspension was lysed in 6M guanidine-HCL buffer and 6HIS-ubiquitinated proteins were 
captured on HisPur Ni-NTA resin (ThermoFisher) while the remaining 20% of sample was 
used to prepare inputs. Pull-down eluates and inputs were separated on SDS-PAGE gels and 
analyzed by immunoblot.
In Vitro Deubiquitination Assay—293T cells were transfected with HA-FOXM1b and 
6xHIS-FLAG-Ubiquitin and separately with FLAG-HA-USP21WT, FLAG-HAUSP21C221A 
and empty vector, respectively. 48 hours following transfection, cells transfected with HA-
FOXM1b/6xHIS-FLAG-Ubiquitin were treated with complete DMEM supplemented with 
25μM MG132 for 1 hour prior to harvesting. HA-FOXM1b/6xHIS-FLAG-Ubiquitin cells 
were lysed in RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 5mM EDTA, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1mg/mL aprotinin and leupeptin, 
10mg/mL leupeptin, 1mM sodium orthovanadate, 1mM NaF, 1mM AEBSF and 20mM 
NEM. FLAG-HA-USP21WT, FLAG-HA-USP21C221A and empty vector cells were lysed in 
RIPA buffer without additional inhibitors. HA-tagged proteins were captured from clarified 
cell lysate on 50μL EZview Red Anti-HA Affinity Gel (MilliporeSigma) according to 
manufacturer’s instructions. Following capture and washing, beads containing captured HA-
FOXM1b/6xHIS-FLAG-ubiquitin were resuspended in DUB Buffer (50mM Tris pH 7.5, 
50mM NaCl, 5mM DTT, 5mM MgCl2) and mixed equally with beads resuspended in DUB 
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buffer containing captured FLAG-HA-USP21WT, FLAG-HA-USP21C221A and empty vector 
cell lysate. Beads were incubated with rotation at 37°C for 4 hours and proteins were eluted 
directly from beads with the addition of Laemlli sample buffer and boiling. Ubiquitination 
status of HA-FOXM1b was assessed by IB as described above.
RT-qPCR—MDA-MB-231 cells were transfected with the indicated siRNA and harvested 
72 hours after transfection. RNA was extracted using RNeasy Mini Kit (QIAGEN) following 
manufacturer’s instructions. 1μg of RNA was used to generate cDNA libraries with random 
primers using SuperScript III Reverse Transcriptase (ThermoFisher) following 
manufacturer’s instructions. Samples were diluted 1:10 and transcript abundance was 
quantified using SsoAdvanced SYBR Green (Bio-Rad) on a QuantStudio 7 Flex Real-Time 
PCR system (ThermoFisher) normalized to GAPDH, with each condition run in triplicates. 
Data displayed as the relative quantity of transcript quantified using the 2−ΔΔCt method 
(Schmittgen and Livak, 2008). All primers used are described in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
TCGA Dataset Analysis—Upper quartile normalized RSEM gene-level data for 1095 
invasive breast cancers were downloaded from the legacy TCGA-BRCA project using the 
NIH Genome Data Commons (https://portal.gdc.cancer.gov/legacy-archive/). Proliferation 
score was calculated for each sample analyzed as previously described (Nielsen et al., 2010) 
and compared to log2-transformed, median-centered FOXM1 expression data for each 
sample analyzed. FOXM1 transcriptional targets were log2-transformed, median-centered 
and compared to log2-transformed, median-centered FOXM1 expression. Gene Set 
Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was 
performed for a previously derived FOXM1 target gene list (Chen et al., 2013) comparing 
USP21-amplified and USP21-non-amplified patient tumors. RPPA normalized data was 
downloaded from the TCGA PanCanAtlas Publication page (http://api.gdc.cancer.gov/data/
fcbb373e-28d4-4818-92f3-601ede3da5e1) and data for 879 breast samples were extracted. 
GISTIC values were downloaded from Broad’s Firehouse (http://gdac.broadinstitute.org/
runs/analyses__2016_01_28/data/BRCA-TP/20160128/gdac.broadinstitute.org_BRCA-
TP.CopyNumber_Gistic2.Level_4.2016012800.0.0.tar.gz). There were 857 samples with 
both RPPA and copy number data. GISTIC values of 2 were considered highly amplified for 
USP1 and compared to those without high amplification of USP21 for volcano plots and to 
compare proliferation score. An FDR-corrected Wilcoxon rank sum test was used to 
calculate proteins associated with USP21 copy number status. Data from 505 breast invasive 
carcinoma samples from TCGA (Cancer Genome Atlas Network, 2012) were downloaded 
from cBioPortal (http://www.cbioportal.org/) (Cerami et al., 2012; Gao et al., 2013). Percent 
of samples with CNA amplification and mRNA overexpression (Z-score threshold ± 2) of 92 
DUBs was aggregated.
Other Statistical Analysis—Analysis of FOXM1 half-life stability was assessed by 
densitometry of bands on immunoblots using ImageJ. Band intensity was calculated for 
FOXM1 and the respective loading control for each lane/time point. Non-specific 
background was subtracted from the signal of each band. FOXM1 intensity at a given time 
point was normalized to the amount of loading control in that lane. For calculating half-life, 
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all time points were calculated as a percentage of initial FOXM1 abundance for each 
respective condition. The best-fit nonlinear regression curve was drawn through points and 
half-life was assed as time when y = 50% using GraphPad Prism 6. Key details of the 
statistical analysis pertaining to RT-qPCR, proliferation assays, paclitaxel sensitivity assays 
and tumor xenograft assays are described in the corresponding Method Details for those 
experiments and in the legends for Figures 3B, 3E, 5A, and 5B, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Cell cycle transcription factor FOXM1 is activated in basal-like breast cancer
• USP21 deubiquitinates FOXM1 via a direct enzyme-substrate relationship
• USP21 promotes cell cycle and paclitaxel resistance in basal-like breast 
cancer
• USP21 is recurrently overexpressed and represents a potential therapeutic 
target
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Figure 1. USP21 Binds and Regulates FOXM1 Abundance
(A) HeLa cells treated with vehicle or 2.5, 5, or 10 mM PR-619 for 8 h were analyzed by 
immunoblot (IB).
(B) HeLa cells were transfected with a pool of four siRNAs targeting respective DUBs. 
FOXM1 stability was assessed by IB 72 h after transfection.
(C) FOXM1 levels were assessed by IB following transfection of Myc-FOXM1b and FLAG-
HA-USP21 in 293T cells 48 h after transfection.
(D) FLAG-FOXM1b and Myc-USP21 were co-expressed in 293T cells. Protein complexes 
were immunopurified with anti-Myc and analyzed by IB.
(E) HA-FOXM1b and Myc-USP21 were co-expressed in 293T cells. Lysates were 
immunopurified with anti-mouse immunoglobulin G (IgG) or anti-HA and analyzed by IB.
(F) Endogenous USP21 was immunopurified from HeLa whole-cell lysates and analyzed by 
IB.
(G) Recombinant 6xHIS-FOXM1b was incubated with recombinant GST-USP21. 
Complexes were captured on glutathione (GSH) agarose beads and analyzed by IB.
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Figure 2. USP21 Protects FOXM1 from Proteasomal Degradation
(A) HeLa cells were transfected with the indicated siRNAs. After 48 h, HeLa cells were 
treated with 10 μM MG132 or vehicle for 6 h.
(B) 293T cells transfected with the indicated plasmids were lysed under denaturing 
conditions and subjected to Ni-NTA pull-down. The ubiquitination status of FOXM1 in each 
condition was assessed by IB.
(C) Top: 293T cells were transfected with the indicated plasmids. After 48 h, 100 ng/mL of 
cycloheximide was added to the cells and samples were taken every 4 h for 16 h. Bottom: 
densitometry analysis performed on corresponding IBs to assess FOXM1 half-life in the 
indicated conditions.
Arceci et al. Page 22













Figure 3. USP21 Affects Growth through Modulation of the FOXM1 Transcriptional Network
(A) FOXM1 transcriptional activity was measured by quantifying luciferase activity in 293T 
cells expressing the 6x-DBE FOXM1 luciferase reporter with and without USP21 
overexpression. Error bars represent SEM.
(B) Relative abundance of FOXM1 target transcripts was assessed by RT-qPCR following 
RNA extraction from MDA-MB-231 cells transfected with the indicated siRNA for 72 h. 
Each condition represents means of triplicates. Error bars represent min-max. *p ≤ 0.05 
based on Student’s t test performed on ΔCt values.
(C) IB of cells used in (B) showing protein levels of various FOXM1 targets.
(D) Mitosis was scored by measuring P-H3-positive cells by flow cytometry in MDA-
MB-231 cells transfected with the indicated siRNA or plasmids following release from 
aphidicolin synchronization at the indicated times.
(E) Growth was measured as the percentage of confluence in the dish every 6 h over 120 h in 
MDA-MB-468 (left) and MDA-MB-231 pINDUCER20 FOXM1b cells (right) treated with 
the indicated siRNAs (or 10 ng/mL of doxycycline) using the IncuCyte live-cell imaging 
system. Each point represents mean of triplicates. Error bars represent SEM. **p ≤ 0.01 
based on linear regression analysis.
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Figure 4. Amplification of FOXM1 and USP21 Is Linked to Proliferation in BLBC
(A) Top: log2 median FOXM1 expression in TCGA breast cancers compared with 
proliferation score and subtype. Bottom: log2 median FOXM1 expression and 7 FOXM1 
target genes ordered by FOXM1 expression. PAM50 breast cancer subtypes: basal like, red; 
HER2 enriched, hot pink; luminal A, dark blue; luminal B, light blue; normal like, green.
(B) Analysis comparing mRNA overexpression (Z score threshold ± 2) and CNA 
amplification of 92 DUBs in 482 tumor samples from the TCGA breast invasive carcinoma 
dataset.
(C) FOXM1 and USP21 abundance assessed by IB in a panel of breast cancer cell lines. 
Breast cancer subtype denoted by color (normal, green; luminal, blue; HER2, pink; BLBC, 
red).
Arceci et al. Page 24













(D) Volcano plot showing protein expression levels in USP21-amplified patient tumors 
based on RPPA data from the TCGA breast cancer dataset.
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Figure 5. USP21 Knockdown Sensitizes BLBC Cells to Paclitaxel
(A) Relative viability of MDA-MB-231 cells (pINDUCER20 FOXM1b transduced) (top), 
MDA-MB-468 cells (middle), and SUM149 cells (bottom) treated with the indicated siRNA 
and exposed to the indicated concentration of paclitaxel (and 10 ng/mL of doxycycline 
[Dox] in siUSP21 + Dox) for 72 h. Each condition represents mean of triplicates. Error bars 
represent SEM. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001 based on two-way 
ANOVA with post hoc pairwise analysis. IB confirming expression of FOXM1 and USP21 
is shown to the right for each corresponding experiment.
(B) Quantification of mean tumor volume of SUM149 mouse xenograft for the indicated 
conditions. For each condition, n = 3. Error bars represent SEM. **p ≤ 0.01 and ***p ≤ 
0.001 based on paired t test of respective measurements.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Aurora A CST Cat# 13092; RRID: AB_2061342
CCP110 Bethyl Cat# A301–343A; RRID: AB_937760
CDK1 Bethyl Cat# A303–663A; RRID: AB_11205291
Cyclin B1 Abcam Cat# ab32053; RRID: AB_731779
Cyclin E1 CST Cat# 4129; RRID: AB_2071200
FLAG M2 Sigma-Aldrich Cat# F1804; RRID: AB_262044
FOXM1 Santa Cruz Cat# sc-502; RRID: AB_631523
GAPDH Santa Cruz Cat# sc-25778; RRID: AB_10167668
Goat Anti-Mouse IgG (H+L) HRP Jackson ImmunoResearch Cat# 115-035-003; RRID: AB_10015289
Goat Anti-Mouse IgG (L) HRP Jackson ImmunoResearch Cat# 115-035-174; RRID: AB_2338512
Goat Anti-Rabbit IgG (H+L) Alexa Fluor 488 Thermo Fisher Cat# A-11034; RRID: AB_2576217
Goat Anti-Rabbit IgG (H+L) HRP Jackson ImmunoResearch Cat# 111-035-003; RRID: AB_2313567
GST Gene Tex Cat# GTX114099; RRID: AB_1949436
HA Covance Cat# MMS-101P; RRID: AB_2314672
Mouse Anti-Rabbit IgG (L) HRP Jackson ImmunoResearch Cat# 211-032-171; RRID: AB_2339149
Myc Santa Cruz Cat# sc-40; RRID: AB_627268
Normal Mouse IgG Santa Cruz Cat# sc-2025; RRID: AB_737182
Phospho-Histone H3 S10 CST Cat# 3377; RRID: AB_1549592
Tubulin Santa Cruz Cat# sc-32293; RRID: AB_628412
USP21 This Paper N/A
Bacterial and Virus Strains
Escherichia coli BL21(DE3) Chemically Competent 
Cells
Thermo Fisher Cat# C600003
Chemicals, Peptides, and Recombinant Proteins
Aphidicolin MilliporeSigma Cat# A0781
Clarity ECL Western Blotting Substrate Bio-Rad Cat# 1705060
Cycloheximide MilliporeSigma Cat# 01810
EZView Red Anti-HA Affinity Gel MilliporeSigma Cat# E6779
Glutathione Agarose Resin GoldBio Cat# G-250–5
HisPur Ni-NTA Resin Thermo Fisher Cat# 88221
Lipofectamine 2000 Thermo Fisher Cat# 11668027
Lipofectamine RNAiMAX Thermo Fisher Cat# 13778150
Matrigel Basement Membrane Mix BD Biosciences Cat# 356234
MG132 Selleck Chemicals Cat# S2619
Nocodazole MilliporeSigma Cat# M1404
Pierce ECL Western Blotting Substrate Thermo Fisher Cat# 32106
PR-619 Selleck Chemicals Cat# S7130
Propidium Iodide MilliporeSigma Cat# P4864
RNase A MilliporeSigma Cat# R6513
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REAGENT or RESOURCE SOURCE IDENTIFIER
SsoAdvanced SYBR Green Bio-Rad Cat# 1725271
SureBeads Protein A and G Bio-Rad Cat# 1614833
TransIT-293 Reagent Mirus Bio Cat# MIR 2700
Zeba Desalting Columns Thermo Fisher Cat# 89889
Peptide (USP21 Antibody): PASGPNPMLRPLPPR This Paper N/A
GST-USP21 This Paper N/A
6HIS-FOXM1b This Paper N/A
Critical Commercial Assays
Luciferase Assay System Promega Cat# E1500
Pierce BCA Protein Assay Kit Thermo Fisher Cat# 23225
PrestoBlue Cell Viability Reagent Thermo Fisher Cat# A13261
QuickChange Lightning Site-Directed Mutagenesis Kit Agilent Cat# 210518
RNeasy Mini Kit QIAGEN Cat# 74104
SuperScript III First-Strand Synthesis System Thermo Fisher Cat# 18080051
Experimental Models: Cell Lines
293T ATCC Cat# CRL-3216; RRID: CVCL_0063
BT474 ATCC Cat# HTB-20; RRID: CVCL_0179
HeLa ATCC Cat# CCL-2; RRID: CVCL_0030
HMEC ATCC Cat# PCS-600–010
MCF10A ATCC Cat# CRL-10317; RRID: CVL_0598
MCF7 ATCC Cat# HTB-22; RRID: CVCL_0031
MDA-MB-231 ATCC Cat# HTB-26; RRID: CVCL_0062
MDA-MB-468 ATCC Cat# HTB-132; RRID: CVCL_0419
SUM149 BioIVT (Astrand) RRID: CVCL_3422
SUM159 BioIVT (Astrand) RRID: CVCL_5423
Experimental Models: Organisms/Strains
Mouse: BALB/c female nude (nu/nu) UNC-CH MP1U N/A
Oligonucleotides




6HIS-FLAG-Ubiquitin Gift from Philippe Soubeyran N/A
6x-DBE FOXM1 Luc Reporter Gift from Michael Whitfield 
(Dartmouth Univ)
N/A
MSCV-FLAG-HA-USP21 Sowa et al., 2009 Addgene Plasmid #22574
MSCV-FLAG-HA-USP21 C221A This Paper N/A
MSCV-FLAG-HA-USP21 siResist This Paper N/A
pDEST-FLAG-FOXM1b This Paper N/A
pDEST-HA-FOXM1b This Paper N/A
pDEST-Myc-FOXM1b 1–160 This Paper N/A
pDEST-Myc-FOXM1b 161–320 This Paper N/A
pDEST-Myc-FOXM1b 235–480 This Paper N/A
pDEST-Myc-FOXM1b 321–480 This Paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
pDEST-Myc-FOXM1b 350–480 This Paper N/A
pDEST-Myc-FOXM1b 400–530 This Paper N/A
pDEST-Myc-FOXM1b 450–580 This Paper N/A
pDEST-Myc-FOXM1b 480–625 This Paper N/A
pDEST-Myc-FOXM1b 481–640 This Paper N/A
pDEST-Myc-USP21 This Paper N/A
pDEST15-GST-USP21 This Paper N/A
pDONR223-FOXM1b This Paper N/A
pDONR223-USP21 This Paper N/A
pET-28b-FOXM1b This Paper N/A
pINDUCER20 Meerbrey et al., 2011 Addgene Plasmid #44012
pINDUCER20-FOXM1b This Paper N/A
pINDUCER20-USP21 This Paper N/A
pLKO.1 shNonT MilliporeSigma Cat# SHC016
pLKO.1 shUSP21 This Paper N/A
Software and Algorithms
FlowJo X FlowJo LLC https://www.flowjo.com
ImageJ https://imagej.nih.gov
Prism 6 GraphPad https://www.graphpad.com
R https://www.r-project.org
Other
CyAn ADP Analyzer Beckman Coulter N/A
IncuCYTE Zoom Essen Bioscience N/A
QuantStudio 7 Flex Real-Time PCR System Thermo Fisher N/A
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